OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator. This document is also available as Markdown.

← British HIV Association

2023-12-31-accounts

==> picture [87 x 51] intentionally omitted <==

2023 Trustees’ Annual Report & Accounts

1

BHIVA | Annual Report & Accounts 2023

www.bhiva.org www.bhiva.org

Contents

s
About BHIVA 4
Year in review 7
The work of the BHIVA subcommittees 10
BHIVA membership annual report to 31 October 2023 19
Structure, governance and management 22
Financial review 24
Statement of Directors’ and Trustees’ responsibilities 25
Appendix 1
Trustees’ Report and Financial Statements 27

Charity information for the year ended 31 December 2023

Trustees retiring on 24 November 2023

Charity Trustees from 24 November 2023

Officers

Elected Trustees

2

BHIVA | Annual Report & Accounts 2023

==> picture [596 x 397] intentionally omitted <==

Specific Trustee Roles

Charity Number

Registered Office and Operational Address

Independent Examiners

Bankers

3

BHIVA | Annual Report & Accounts 2023

About BHIVA

The British HIV Association, (BHIVA), is the leading UK association representing professionals in HIV. Since its inception in 1995, BHIVA has been committed to providing excellent care for people living with and affected by HIV.

BHIVA is a national advisory body on all aspects of HIV care and the association provides a national platform for HIV care issues. BHIVA representatives contribute to international, national and local committees dealing with HIV care. In addition, BHIVA promotes undergraduate, postgraduate and continuing medical education within HIV care.

The association aims to advance professional and public education in the subjects of HIV, including testing, treatment and prevention, and the management of HIV-related illnesses and treatment complications through the promotion of research, dissemination of and the production and promotion of evidence-based guidelines and standards.

  1. To support other organisations through activities including collaborative responses to consultations, media representation of HIV, workforce planning and, exceptionally, individual cases of stigma, discrimination or suboptimal care

Long term, continuing to promote best practice within the specialty, ensuring that the care provided for people living with HIV in the UK is world-leading is of primary concern. To achieve that aim, BHIVA must maintain its contribution to the continued growth of the specialty over the next decade by continuing to support training and research in the field of HIV medicine and helping to ensure that the existing excellent national standards of care are maintained.

Our objectives

BHIVA has four main objectives:

  1. To relieve sickness and to protect and preserve health through the development and promotion of good practice in the testing and treatment of HIV and HIV-related illnesses:

  2. To advance public and professional education on HIV through education and the promotion, conduct and dissemination of research

  3. To promote optimal outcomes for people living with, and affected by, HIV through the development and dissemination of national guidelines and standards, audit and research

Education is a primary focus and BHIVA is passionate about promoting and supporting the speciality to deliver undergraduate, postgraduate and continuing medical education within HIV care.

With work still to be done in educating the medical profession, scientific community public about HIV, through the promotion of research and dissemination of research results is central to the association’s objectives. Promoting accurate messaging related to HIV and challenging decisions that discriminate against people living with, or affected by, HIV helps overcome outdated beliefs and challenge stigma.

4

BHIVA | Annual Report & Accounts 2023

Education is also key to the ongoing development of the speciality and the ability to develop a fully integrated educational programme for members and the wider HIV community is at the heart of the long-term strategy of the association. Promoting and disseminating the latest research through regional, national and international meetings and conferences and publications, and supporting an increasingly diverse range of research studies which aim to improve the health and lives of people living with HIV will help to achieve this.

By increasing the awareness of BHIVA at an international level, BHIVA endeavours to maintain a reputation for excellence education and research. The association’s ability to support a range of stakeholders and organisations by providing expert clinical advice on HIV and its management further strengthens BHIVA’s international presence.

Activities

BHIVA promotes excellence in HIV care through production of evidence-based, NICEaccredited guidelines. Our antiretroviral treatment guidelines form the basis of national prescribing policies across the UK and are widely read and referenced internationally. BHIVA represents the interests of people with HIV and input from the HIV clinical and research communities through feedback on national prescribing policies. Antiretrovirals moved under the remit of NICE for the first-time last year and BHIVA provided strong written feedback and verbal representation at the NICE Technology Appraisal for the first generation of injectable HIV treatment in 2021. BHIVA works closely with other professional and community organisations to advocate against discriminatory policies and ensure that the needs and priorities of people with HIV are at the heart of decisions that affect them.

BHIVA actively encourages the presentation of original UK research. Abstracts are invited for the annual spring conference, which aims to showcase the best contemporary research into HIV-related topics currently being undertaken in the UK. The annual conference attracts a broad spectrum of participants from experienced HIV specialists to those still in training, HIV researchers from a range of disciplines and community members. Eminent international speakers are invited to present the latest data.

BHIVA supports research in HIV care through its annual Research Awards Scheme. Originally launched in 2006, the programme operates through competitive application. Open to all BHIVA members applicants can submit applications for the funding of research projects that impact on the improvement of clinical care and management of people living with HIV in the UK. A minimum of £30,000 per annum is available, to be distributed amongst the successful applicants according to the quality of the submitted proposals. The awards panel is chaired by an independent chair.

Applications for grants or funding for research or other projects made directly to the association are reviewed by the BHIVA Executive Committee on a quarterly basis and considered based on merit and relevance to the objectives of BHIVA.

HIV Medicine is the official journal of the association and is published by Wiley. HIV Medicine is a peer-reviewed journal publishing original articles, reviews and guidelines on all aspects of HIV treatment and diagnosis.

==> picture [156 x 188] intentionally omitted <==

5

BHIVA | Annual Report & Accounts 2023

BHIVA also undertakes a wide range of other activities to promote medical education in HIV care and support research. This includes conference feedback meetings, training courses for the Diploma in HIV Medicine examination, web-based e-learning modules as well as international scholarships and exchanges to forge links with international organisations to increase the understanding of the treatment and management of HIV.

A board of 18 trustees are responsible for the work of the association and its activities are carried out by five main sub-committees, all which report to the Executive Committee. The sub-committees are:

The Executive Committee review the work carried out by the sub-committees to ensure its activities are in line with the charity’s objectives. All trustees sit on at least one sub-committees to facilitate this process and monitor progress.

BHIVA would be unable to flourish without the considerable commitment of time, energy, expertise and dedication by so many individual members of the committees, sub-committees, writing and working groups as well as the vital support through sponsorship from within the pharmaceutical industry.

==> picture [156 x 188] intentionally omitted <==

6

BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

Year in review

Throughout 2023, BHIVA has continued its commitment to supporting people living with and affected by HIV.

Following our Equity, Equality, Diversity and Inclusion (EEDI) review which was conducted by an independent expert group and presented at our BHIVA Spring meeting, we have established a new EEDI working group to implement the findings of the review and to advise BHIVA’s Executive Committee on all guidelines, sub-committees and strategic plans.

==> picture [83 x 116] intentionally omitted <==

We updated many of our guidelines including those on opportunistic infections and antiretroviral therapy, as well as some of our e-learning modules. In addition, we produced rapid guidance on the assessment and management of cardiovascular risk in people living with HIV in response to the REPRIEVE study – the first organisation globally to do this. All our guidelines remain available online on our website and in patient-friendly versions. We have begun a redesign of our website which remains a pillar of BHIVA’s information sharing and are looking forward to sharing our upgraded website with a new layout, functionality and colour theme.

BHIVA continued to be a mainstream media commentator on matters relating to HIV, featuring on a wide range of media outlets, including radio and television. The People First Charter has been increasingly adopted by significant HIV organisations nationally and internationally such as Lancet HIV, EACS and HIV in Women’s Workshop, moving to remove stigma through non blaming and appropriate use of language in the context of HIV.

BHIVA’s conference schedule kicked off with ever-popular virtual CROI feedback sessions. We held our BHIVA Spring Conference 2023 in Gateshead – our first in-person conference since COVID, with excellent feedback. 2023 culminated with our globally themed Autumn Conference and World AIDS Day in Bishopsgate, London - a new venue for BHIVA and very popular with presenters, exhibitors and attendees alike.

Our audit programme is internationally renowned and this year we performed a national audit of engagement in care, the findings of which were presented at our Autumn Conference in November 2023. BHIVA also provided advice and support to the ECDC and EACS on the development of their first Standards of Care.

2023 was another busy year for the Education and Scientific sub-committee with the announcement of £70,158 to six successful applicants for our coveted BHIVA Research Awards.

All in all 2023 was a great year for BHIVA – well done everyone!

BHIVA | Annual Report & Accounts 2023 7

CIRCULATION

Global reach

In 2023, 7,284 institutions offered access to the latest content in your journal via a Wiley license or a traditional subscription. On this map, darker shading shows where circulation is highest. Countries/regions with no shading may be covered by philanthopic initiatives. In 2023, our philanthropic initiatives extended

==> picture [207 x 129] intentionally omitted <==

Reach by region

This table shows the number of institutions, by region, with access to the latest content in your journal via either a Wiley license or a traditional subscription.

==> picture [426 x 146] intentionally omitted <==

----- Start of picture text -----
SALES MODEL 2021 2022 2023
Australia & NZ 462 463 463
Canada 88 91 95
China 112 114 149
Europe 3 3,240 3,058 3,046
Japan 178 192 186
Rest of World 2,052 2,104 2,151
UK 293 297 307
USA 747 836 887
Grand Total 7,172 7,155 7,284
----- End of picture text -----

Reach by access type

In 2023, 7,282 institutions offered access to your journal via a Wiley license, often through a consortium. Of these institutions, 1,738 had access via the ‘All Journals license’. 3,297 institutions had access via ‘Transformational agreements’ which cover both subscription access and open access publishing. In addition, 2 institutions offered access via traditional (online or print) subscriptions.

==> picture [208 x 171] intentionally omitted <==

----- Start of picture text -----
REGION 2021 2022 2023
Institutions with access
7,170 7,153 7,282
via a Wiley license
All Journals license 2,347 1,340 1,738
Transformational
1,398 2,825 3,297
agreements
Other licenses 3,425 2,988 2,247
Institutions with access via
2 2 2
traditional subscriptions
Online 1 1 1
Print and online 0 0 0
Print 1 1 1
Total 7,172 7,155 7,284
----- End of picture text -----

Additional reach: EBSCO

Wiley’s arrangement with EBSCO allows us to extend the reach of your journal beyond core academic libraries. In 2023, 1,318 institutions accessed embargoed content of at least one year old from your journal via EBSCO databases.

==> picture [84 x 116] intentionally omitted <==

This is a -2.5% change from 2022.

8

BHIVA | Annual Report & Accounts 2023

Social Media Reach

==> picture [58 x 57] intentionally omitted <==

With over 3,000 followers, the BHIVA Facebook page is managed by the External Relations sub-committee and is used as a tool for promoting the work of the association. It carries updates and links to valuable resources produced by both BHIVA and other organisations within the HIV healthcare sector.

The BHIVA X account, also managed by the External Relations subcommittee, has continued to go from strength to strength again in 2023 and now has over 12,500 followers, an increase from over 10,000 followers in 2022. The group post regularly about the latest updates in the field of HIV and there were approximately 850,000 post impressions across the 12 months.

BHIVA’s YouTube channel is used to host the latest resources, including a series of educational podcasts covering a range of hot topics in HIV. Following its set up in 2019, the YouTube channel has become an excellent resource for the broadcast of educational content including sessions from conferences and other training materials.

The BHIVA Instagram account has become increasingly active over the year and we now have 1,500 followers.

==> picture [156 x 188] intentionally omitted <==

9

BHIVA | Annual Report & Accounts 2023

The work of the Sub-Committees

AUDIT AND STANDARDS SUB-COMMITTEE

Professor Fiona Burns, Chair Audit & Standards Sub-committee

The BHIVA Audit and Standards sub-committee runs a routine clinical audit program with HIV centres across the UK to improve quality of care. The main 2023 project was a national audit of engagement in HIV care. It included a survey of HIV services’ policies and practices, a case-note review of inpatients with HIV to assess admission causes (e.g., undiagnosed or not in care), and a review of outpatients not seen for over a year, focusing on disengagement and re-engagement efforts. Key findings and recommendations were presented at the BHIVA Autumn Conference in November 2023, with individual feedback reports sent to services. A paper is being prepared for submission.

The 2024 BHIVA national audit will aim to assess UK-wide HIV clinical services’ documentation of co-medications and provision of vaccinations. Other key areas of focus will include communication with GPs, new BHIVA guidance regarding statins and provision of long-acting injectable ART. The audit will have two parts: a brief survey of services’ policies on documentation of co-medications, and a casenote review of outpatients living with HIV who have been on the active outpatient caseload and attended an appointment in the last 12 months.

BHIVA and the UK Health Security Agency (UKHSA) continue to collaborate on understanding the causes and preventable

mortality among people with HIV through the National HIV Mortality Review (NHMR). The NHMR working group met twice during this period, involving regional representatives and specialists to review progress. The data collection platform is being updated to give clinicians more autonomy and to integrate with late diagnosis reviews.

The sub-committee reviewed the PROM tool developed through the work led by Prof R Harding and endorsed its appropriateness. They recommended using the HIV positive outcomes measure, whilst further validation is in progress.

BHIVA is collaborating with the British Psychological Society to update psychological support standards for adults with HIV, aiming for publication by the 2024 BHIVA Autumn Conference.

sub-committee members led a survey of emergency departments implementing HIV and hepatitis B/C screening, focusing on the acceptability and understanding of assumed consent. The findings will be presented presented as a poster at the BHIVA 2024 Spring Conference and are being prepared for a journal paper.

Sub-committee members are supporting and advising on the ECDC/EACS Standards of Care. In 2023, they finalised and presented the first two modules—HIV pre-exposure prophylaxis and HIV testing—at the EACS 19th European AIDS Conference. They also aided in the ECDC survey on HIV-related stigma in healthcare,

==> picture [84 x 116] intentionally omitted <==

10

BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

which gathered over 18,400 participants from 54 countries, including 1,569 from the UK. The report is published here. Modules for 2024 in development include ART initiation, co-morbidity management, and antenatal screening.

Since the last report, the Sub-committee has successfully appointed a Vice Chair. The Sub-committee extends its sincere gratitude to Ann Sullivan and Andrew Freedman, who both retired this year after many years of dedicated service.

BHIVA CONFERENCES SUB-COMMITTEE REPORT

Dr Nicky Mackie, Chair Conferences Sub-committee

The first organised events of 2023 were the ever-popular Best of CROI webinars. Since these moved to a virtual platform, the feedback to continue in this format has been consistent and resounding. The Conference on Retroviruses and Opportunistic Infections 2023 was a (mainly) face-to-face event that took place in Seattle, Washington in February. BHIVA supported a small working party to attend (made possible by grants from pharmaceutical companies) to review the key research. This group worked hard to produce slides and pre-record talks for the webinars which took place on 2 different evenings shortly after the Conference. We had around 150 attendees at each event and there was a live panel discussion with Q&A after the recordings. Feedback was excellent although many acknowledge how hard it is to fit in so much key data into short talks!

==> picture [155 x 188] intentionally omitted <==

A huge amount of work from the Conferences Committee and the Medivents team went into the planning for the BHIVA Spring Conference at the end of April – a first time for BHIVA in Gateshead. I was particularly excited as this was my first in-person Conference since prepandemic! 170 abstracts were submitted for review. The programme featured a variety of invited speakers covering a range of topics including co-morbidities, the care cascade and patient–reported outcome measures; there were 4 oral abstract sessions where novel research was presented by a variety of health care workers

BHIVA | Annual Report & Accounts 2023 11

and community representatives; and more than 130 posters. There was also the opportunity to hear the results from the Equality, Equity, Diversion and Inclusion review which resulted in some lively discussion.

==> picture [207 x 140] intentionally omitted <==

----- Start of picture text -----
LIVE EVENT
BHIVA SPRING BHIVA SPRING
2022 2023
ABSTRACT
157 170
SUBMISSIONS
ABSTRACT
144 164
ACCEPTED
ORAL
20 20
PRESENTATIONS
POSTER
124 141
PRESENTATIONS
----- End of picture text -----

I would like to take this opportunity to thank the Conferences Committee for their hard work and for the enthusiasm that they contribute to the planning of BHIVA’s meetings and educational events. I have now completed 3 years as Conference chair (including through the pandemic), a role which I have hugely enjoyed, and I am handing over the reins to Professor Caroline Sabin who I have no doubt will do a fantastic job.

The overwhelming enthusiasm to be able to attend a conference in person, meet old friends and colleagues, listen to unique research and state-of-the-art lectures was expressed by multiple attendees and the feedback around content was very positive.

November 2023 was a busy month for the team. The ever-popular BHIVA General Medicine Course was held early in the month – a great opportunity for HIV/GU physicians to hear what’s new in the ever-changing world of medicine.

On Friday 24th November, we held our BHIVA Autumn Conference which culminated in a celebration of World AIDS Day. The meeting was held in a venue in Bishopsgate, London (which proved to be a hit! thank you Medivents…) and had a global theme with topics covering migration and HIV, lessons learned for the UK from global policies and practice and opportunistic infection management. The evening event had contributions from all 4 nations across the UK and there was a very buoyant atmosphere at the post-Conference drinks afterwards!

==> picture [156 x 188] intentionally omitted <==

12

BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

EDUCATION AND SCIENTIFIC SUB-COMMITTEE REPORT

Dr Tristan J Barber, Chair, Education & Scientific Sub-committee

It has been a busy year again for the Education and Scientific sub-committee in 2023, with work on a our Research Awards Programme as well as education, ably led by sub-committee Vice Chair and Education Lead Dr Ashini Fox.

Professor Alison Rodger chaired the BHIVA Research Awards Judging Panel for the second time. These Awards are supported by Gilead Sciences and BHIVA members, providing funding for research projects that will impact on the improvement of clinical care, management, health, and wellbeing of people living with HIV and on the prevention of HIV transmission. Applicants must be from UK based institutions. We announced six successful applicants who were awarded a total of £70,158.16:

Sadly no one was eligible for the Don Jeffries Research Award this year, but we are hoping there will be eligible candidates soon. Professor Maryam Shahmanesh is Chair of the BHIVA Implementation Science Awards judging panel. These awards are supported by ViiV Healthcare. Whilst we did not make awards in 2023, further rounds not mentioned occurred in 2022 and were after the previous report.

Dr Flavien Coukan

Imperial College London

‘Modifiable factors to HIV PrEP access: a qualitative study to investigate codesign strategies to develop new PrEP delivery and accessibility recommendations in underserved populations in England’

Dr Mimie Chirwa

Bedfordshire Hospitals NHS Foundation Trust ‘HIV testing within faith communities in Luton’

Dr David Lawrence

==> picture [83 x 116] intentionally omitted <==

King’s College Hospital NHS Foundation Trust ‘Implementing long-acting injectable antiretroviral therapy for people living with HIV who have chronic viraemia’

Dr Shema Tariq

University College London

‘The PRIME clinic: implementing holistic support for women living with HIV transitioning through the menopause’

Further funding is being sought to run another round of Implementation Science Awards. The BHIVA international Partnerships Working Group (IPWG) is chaired by Dr Douglas Fink, supported by Vice Chair Dr Nadia Ahmed. The BHIVA/Gilead International Exchange Fellowship Awards are designed to support the development of new links between BHIVA and institutions in low- or middle-income countries.

13

BHIVA | Annual Report & Accounts 2023

Funding has been secured to run a round of applications in 2024. The BHIVA IPWG also held their first lunchtime workshop at the BHIVA spring conference in April 2023, showcasing work in Indonesia and Nigeria, with another delivered in 2024 (details in next year’s report). The Education working group, Chaired by Dr Ashini Fox, has continued to develop our online resources.

In 2023, an E-learning assessment module on HIV-2 management was published and several e-learning modules based on chapters of the opportunistic infection (OI) guidelines were developed to be published post pilot. E-learning modules became open access with the option of completing anonymously which has led to a significant increase in usage. E-learning modules continue to receive positive feedback and be seen as a valuable exam revision resource for the Diploma in HIV Medicine, and as continuing professional development (CPD) for senior clinicians.

Future plans

2024 will see some changes. Tristan Barber has stepped down as Chair after 4 years in the role, and the process is underway to find a replacement. Ashini Fox has stepped down as Vice Chair, but remains Education Lead, and Professor Alison Rodger will complete her third and final year as Research Awards Judging Panel Chair.

We are looking forward to continuing to see the subcommittee thrive, including through expanding the educational resources available to members and beyond. The Education and Scientific subcommittee is at the core of BHIVA activities, including in supporting conference delivery, the membership with educational content, and in obtaining funding to support BHIVA’s research, implementation science, and international educational exchange programmes.

Professor Anna Maria Geretti continues to provide a monthly summary of the BMJ journal Sexually Transmitted Infections for BHIVA Members Matters, and Dr Laura Waters also helpfully provides a summary of the HIV Medicine journal and other highlights.

HIV Medicine (https://onlinelibrary.wiley. com/journal/14681293) is the official journal of BHIVA with all eligible members getting complementary access. The Editors-in-Chief are Professor Caroline Sabin and Professor Jürgen Rockstroh, and the journal achieved an impact factor of 2.8 in 2023.

==> picture [156 x 188] intentionally omitted <==

14

BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

BHIVA EXTERNAL RELATIONS SUB-COMMITTEE REPORT

Dr Matthew Page, Chair, External Relations Sub-Committee

Statements

BHIVA have produced position statements on the use of the shingles vaccine for people living with HIV (2023).

The External Relations Subcommittee works in line with BHIVA’s objectives to promote good practice in the treatment and care of HIV to its membership and external organisations.

Summary Of Activities

Organisation structure

The External Relations committee membership changes have been maintained since its restructuring in 2021.

Media

BHIVA continues to be a mainstream media commentator on HIV, responding to many media enquries. BHIVA spokespeople were featured on a wide range of media outlets, including, Radio (BBC Radio 4, BBC Radio 5, City Radio, Virgin Radio Pride), television (Talk TV

Social Media

The External Relations Committee continues to manage BHIVAs social media accounts, which include Twitter, Facebook and Instagram, as well as the HIV Medicine Journal Twitter account. There continues to be growth in followers on all platforms and continues to be an effective method for dissemination of information, and communication with members and external organisations. In this Jun 2023, we have additionally opened a BHIVA LinkedIn account which is doing well.

We have opted to pay for one off analytics for conferences to obtain key information which demonstrates social media impact to our stakeholders.

October 2023 saw the Landmark endorsement for the People First Charter - Lancet HIV. It has since been adopted by numerous organisations internationally.

BHIVA is still in ongoing discussions with the British Boxing Board of Control regarding a ban on boxers living with HIV.

We continue to promote the external BHIVA Equity, Equality Diversity and Inclusion (EEDI) review

==> picture [83 x 116] intentionally omitted <==

We have successfully completed the rounds of media training for BHIVA Executive committee in an attempt to expand our resource to rapid response news items.

BHIVA | Annual Report & Accounts 2023 15

Succession planning ongoing for BHIVA tweeters – successfully filled posts for present tweeter roles.

BHIVA GUIDELINES SUB-COMMITTEE REPORT

Dr Clare van Halsema, Chair Guidelines Sub-Committee

Looking Ahead – 2023 and onwards

BHIVA produces guidelines on a comprehensive range of topics to support clinicians in managing HIV and its complications, as well as working with other organisations to produce co-badged guidelines on HIV prevention, testing and other areas. In a rapidly changing area of health, we provide rapid guideline updates as needed.

Dr Stuart Flanagan took on the chair role in autumn 2023, after Dr Clare van Halsema completed a three-year term. Dr Angela Bailey continued as vice chair and Dr Cathy Nieman Sims continues her permanent role as guidelines coordinator.

The guidelines subcommittee has continued to meet virtually and has agreed not to return to face to face meetings following the COVID pandemic.

Guideline development

A newly updated chapter of the opportunistic infections guideline, being updated chapter by chapter, was published in 2023, on the clinical management of pyrexia of unknown origin.

The full guidance on antiretroviral therapy from 2022 was updated in 2023 with a clarification on cardiovascular risk assessment. The tuberculosis guideline, now undergoing full review, was updated with a change based on a systematic review and to align with WHO on the timing of antiretroviral therapy for people taking TB treatment.

==> picture [156 x 188] intentionally omitted <==

16

BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

Rapid guidance on statins for people living with HIV, following the REPRIEVE study was published in November 2023. It generated some discussion and feedback, including a letter from a group of cardiologists, and an update was published in early 2024. This is a new area of practice, in which BHIVA has rapidly responded to new research findings.

Rapid guidance usually does not undergo consultation, but feedback is invited using a form alongside the guidance on the BHIVA website. However, we did invite consultation on the rapid guidance on opt-out testing, in view of the importance, lack of published evidence and range of opinions.

Work is ongoing on full guideline updates in viral hepatitis, immunisation, monitoring, HIV in pregnancy and now tuberculosis, in 2024.

Abridged versions of guidelines are published on the BHIVA guidelines app.

2024 plans and actions so far

Work is ongoing on chapters of the opportunistic infection (OI) guideline, including non-tuberculous mycobacteria, OIs in pregnancy, central nervous system OIs.

The tuberculosis guideline update has begun.

E-learning modules on the various chapters are written – and the non-tuberculous mycobacteria module is ready as the chapter is published.

A new guideline has been agreed to support engagement in care – the “not in care” guidelines..

The updated pregnancy guideline is in the final stages of consultation.

With new members of the Guidelines Sub-committee including community representatives, trainee member and members responsible for the app, linkage with the education group for modules, we continue to produce guidance that is of great value to the HIV community.

Position statements

A position statement was published on shingles vaccine for people living with HIV in December 2023 in response to changes in national recommendation for shingles vaccine

NICE accreditation

We held NICE accreditation for our guideline process until December 2023. NICE has now reviewed its accreditation process and has terminated it as of July 2024. We continue to adhere to the principles of excellence in evidence-based, unbiased guideline production as set out in the guideline development manual.

==> picture [155 x 188] intentionally omitted <==

BHIVA | Annual Report & Accounts 2023 17

18 BHIVA l- 1nn14aliiifvoi.l &.Accounls 2U25

==> picture [596 x 58] intentionally omitted <==

BHIVA membership annual report to 31 October 2023

TOTAL NUMBER OF MEMBERS FROM YEAR 2010 TO 2023

==> picture [458 x 154] intentionally omitted <==

----- Start of picture text -----
1200
1028
1000 1004 999 995 1002
960 949 943
908
884
800 790
758 744 754
600
400
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2022
Number of members
----- End of picture text -----

COMPARISONS OF CATEGORY AND REGION

==> picture [482 x 374] intentionally omitted <==

----- Start of picture text -----
2023 TREND 2022
MEMBERSHIP CATEGORY
No % % No %
Consultant 354 45%  364 48%
Specialty trainee 91 11% N/A 0 0%
Medical student 76 10%  7 1%
BHIVA Affiliated 74 9%  73 10%
Non-consultant 37 5%  196 26%
BHIVA UK-CAB 30 4%  36 5%
BHIVA International (HMIC/ LMIC) 26 3%  31 4%
Academic, Clinical, Health or
26 3% N/A 0 0%
Population Scientist
Pre-specialty trainee 25 3% N/A 0 0%
Life member 22 3% = 20 3%
Retired consultant 17 2% = 16 2%
Annual member 12 2%  11 1%
Total BHIVA members 790 100% 754 100%
BHIVA |
----- End of picture text -----

BHIVA | Annual Report & Accounts 2023 19

==> picture [459 x 277] intentionally omitted <==

COMPARISONS OF CATEGORY AND REGION

==> picture [459 x 277] intentionally omitted <==

20

BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

SUMMARY OF MEMBERS NOT RENEWING BY 31 OCTOBER 2023

==> picture [426 x 83] intentionally omitted <==

----- Start of picture text -----
MEMBERS NOT RENEWED 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
Total cancellations 33 18 19 39 20 23 29 40 39 33 40 38
Not renewed (lapsed) 127 69 94 212 101 149 116 112 109 79 99 79
Total 160 87 113 251 121 172 145 152 148 112 139 117
----- End of picture text -----

==> picture [427 x 194] intentionally omitted <==

----- Start of picture text -----
YEAR 2023 TREND YEAR 2022
REASON FOR CANCELLATION
No % % No %
Retired 14 43%  6 33%
No reason given/Other 7 21%  5 28%
Medical Student unsubscribed 5 15% N/A 0 0%
Parental leave 4 12%  3 17%
Financial pressures 2 6%  0 0%
No longer working in HIV 1 3%  3 17%
Sabbatical leave 0 0%  1 5%
Total cancelled members 33 100% 18 100%
----- End of picture text -----

==> picture [540 x 335] intentionally omitted <==

----- Start of picture text -----
YEAR 2023 TREND YEAR 2022
PREVIOUS MEMBERSHIP CATEGORY
No % % No %
Affiliated 15 9%  9 10%
Consultant 46 29%  18 21%
International 12 7%  3 3%
Medical student 6 4%  1 1%
Non-consultant 65 41%  45 52%
Retired 4 3%  5 6%
UK-CAB 12 7%  6 7%
Total non-renewed members 160 100% 87 100%
BHIVA | Annual Report & Accounts 2023
----- End of picture text -----

BHIVA | Annual Report & Accounts 2023 21

Structure, governance and management

BHIVA is a Charitable Incorporated Organisation (as of 12 December 2016) governed by its Constitution and registered as a charity with the Charity Commission.

BHIVA is a membership association currently governed by a Board of 18 elected trustees who make up the Executive Committee including four officer posts of Chair, Vice Chair, Honorary Secretary and Honorary Treasurer.

BHIVA endeavours to ensure that the specialty is well represented on the Executive Committee to ensure that local challenges and issues that affect all those working within the field are addressed UK wide. Trustees are drawn from across the HIV sector and include clinicians and other healthcare professionals, academics, a representative from the UK-CAB as well as a trainee Doctors’ representative and a new Consultant Doctors’ representative.

The methods adopted for the recruitment and appointment of new trustees are as follows:

Nominees are required to complete a trustee declaration form, a conflict-of-interest form and a skills assessment form at time of nomination. All members of the Executive Committee give their time voluntarily and receive no paid benefits from the charity.

On joining the BHIVA Executive Committee, trustees are provided with an induction pack that includes an outline of the role and expectations, a copy of the constitution, relevant policy and administration documents required to carry out the role as well as Charity Commission information about the responsibilities of becoming a charity trustee. Each new trustee also undertakes a tailored induction programme and is offered mentoring support from existing trustees.

Beyond their governance duties, trustees are expected to take an active role in the work of the charity according to their expertise through engagement with at least one of the five specialist sub-committees. Each sub-committee manages the activities of the charity and is led by a chair and vicechair. Under the sub-committees also sit a variety of specialist working and writing groups, led by an elected or appointed BHIVA member, who has specific responsibilities and bring a depth of knowledge and expertise to the sub-committees.

22

BHIVA | Annual Report & Accounts 2023

The trustees hold quarterly Executive Committee meetings to review the activities of the charity and consider its plans.

To retain its position at the forefront of HIV care, BHIVA is also affiliated with all the other key charities and associations who work within the field including:

BHIVA has developed important links with other organisations, encouraging exchange of information between national and international centres including:

==> picture [156 x 188] intentionally omitted <==

23

BHIVA | Annual Report & Accounts 2023

Financial review

BHIVA continues to face some financial headwinds arising from increased costs and downward pressure on income.

Increased costs have largely been driven by inflation and relate to increases in conference venue costs, operational costs, and pay uplifts for staff involved in, for example, the production of guidelines. Income from HIV medicine remained reasonably stable in 2023, but it is anticipated that this will fall in 2024. While membership has increased in number, owing to the type of membership class, there has been a slight fall in income from this source. There has also been a modest fall in overall income from the conferences, although registration has held up well. BHIVA has benefited from a modest increase in pharmaceutical sponsorship, which remains an important source of annual income.

Overall, BHIVA remains in a reasonably good financial position and there are no serious concerns about our ability to continue charitable activities in the near future. Further scrutiny of costs continues as well as looking at opportunities to raise income. Work towards a more granular approach to budgeting has been undertaken in 2024 and will continue in 2025. Major risks to BHIVA’s continuing charitable activities remain the reduction in pharmaceutical company sponsorship and wider economic uncertainty.

There has been a modest decline in net cash and cash equivalents held by BHIVA and it is anticipated that this will continue in 2024 to cover costs such as the website redesign. There was a small improvement in the value of and return on the investment fund. It is anticipated that this will accelerate in 2024, although significant uncertainty remains about future performance, in the context of current economic and geopolitical circumstances.

24 BHIVA | Annual Report & Accounts 2023

Statement of Directors’ and Trustees’ responsibilities

The trustees are responsible for preparing a trustees’ annual report and financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the charity trustees to prepare financial statements for each year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, of the charity for that period. In preparing the financial statements, the trustees are required to:

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the applicable Charities (Accounts and Reports) Regulations, and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the charity and taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity’s website in accordance with legislation in the United Kingdom governing the preparation and dissemination of financial statements.

25 BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

TRUSTEE DECLARATION

I declare that:

I do not have any financial interests in conflict with those of BHIVA (either in person or through family or business connections) except those that I have formally notified in a declaration of interest statement. I will specifically notify any such interest at any meeting where trustees are required to make a decision, which affects my personal interests, and I will absent myself entirely from any decision on the matter and not vote on it.

==> picture [292 x 162] intentionally omitted <==

==> picture [292 x 162] intentionally omitted <==

==> picture [293 x 162] intentionally omitted <==

==> picture [293 x 162] intentionally omitted <==

BHIVA | Annual Report & Accounts 2023 26

Financial Statements for the year ended 31 December 2023

==> picture [311 x 310] intentionally omitted <==

27

BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

Contents

Contents
Reference and administrative details 29
Trustees’ Report (including directors’ report) 30
Independent Examiner’s Report 32
Statement of Financial Activities 33
Consolidated Balance Sheet 35
Consolidated Cashfow Statement 37
Notes to the Financial Statements 38

28

BHIVA | Annual Report & Accounts 2023

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees

Professor Y Gilleece Dr T Barber Dr D Clutterbuck Dr L N Siriwardena Dr H Pintilie Ms N Naous Dr C Emerson Dr K Childs Mr J R Jaquiss Dr N Mackie Dr D Chadwick Professor C Sabin Dr I Reeves Dr J Underwood

Charity number 1170707

Principal address

BHIVA Secretariat, Spirella Building, Bridge Road , Letchworth Garden City, Herts SG6 4ET

Independent examiner

UHY Hacker Young Suite 501 The Nexus Building Broadway Letchworth Garden City Herts SG69BL

Bankers

National Westminster Bank plc, 190 The Broadway, Muswell Hill, London N10 3SO Santander Bank, Bootle, Merseyside L30 4GB

Solicitors

Stone King LLP, Boundary House, 91 Charterhouse Street London EC1M 6HR

29

BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

TRUSTEES’ REPORT (INCLUDING DIRECTORS’ REPORT) FOR THE YEAR ENDED 31 DECEMBER 2023

==> picture [448 x 596] intentionally omitted <==

BHIVA | Annual Report & Accounts 2023 30

TRUSTEES’ REPORT (INCLUDING DIRECTORS’ REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

==> picture [448 x 560] intentionally omitted <==

31

BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

INDEPENDENT EXAMINER’S REPORT

TO THE TRUSTEES OF BRITISH HIV ASSOCIATION

28 October 2024

32

BHIVA | Annual Report & Accounts 2023

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 2023

==> picture [448 x 429] intentionally omitted <==

33

BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

CIO STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 DECEMBER 2023

==> picture [447 x 427] intentionally omitted <==

34

BHIVA | Annual Report & Accounts 2023

CONSOLIDATED BALANCE SHEET AS AT 31 DECEMBER 2023

==> picture [448 x 572] intentionally omitted <==

35

BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

CONSOLIDATED BALANCE SHEET AS AT 31 DECEMBER 2023

==> picture [447 x 570] intentionally omitted <==

36

BHIVA | Annual Report & Accounts 2023

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2023

==> picture [448 x 572] intentionally omitted <==

37

BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

==> picture [447 x 570] intentionally omitted <==

38

BHIVA | Annual Report & Accounts 2023

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

==> picture [448 x 594] intentionally omitted <==

39

BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

==> picture [447 x 570] intentionally omitted <==

40

BHIVA | Annual Report & Accounts 2023

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

==> picture [448 x 572] intentionally omitted <==

41

BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

==> picture [447 x 570] intentionally omitted <==

42

BHIVA | Annual Report & Accounts 2023

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

==> picture [448 x 572] intentionally omitted <==

43 BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

==> picture [447 x 570] intentionally omitted <==

44

BHIVA | Annual Report & Accounts 2023

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

==> picture [448 x 572] intentionally omitted <==

45

BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

==> picture [447 x 570] intentionally omitted <==

46

BHIVA | Annual Report & Accounts 2023

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

==> picture [448 x 572] intentionally omitted <==

47

BHIVA | Annual Report & Accounts 2023

==> picture [596 x 58] intentionally omitted <==

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

==> picture [447 x 570] intentionally omitted <==

48

BHIVA | Annual Report & Accounts 2023

Hackeryoung Chanered A(counthn15 23083n318926 23 (ktober 2024 UHY Trf8(lerY4)Wy PO 501 Th* NEXUS roadway ritish HIV Ass<)eiation Sp1￿Ma Buildins Bridge Road LetthworthGardenCity HcEts HeitssGs￿L +44 1462 S83333 +44 1462687334 Fax Em•1 SG6 4Er Also th ¢¥rnbrfdyeaHd Dear Sir5 Durin8 the course of our independent examination of your accounls lor ihe year ending 31 Deeember 2023, the followins Tepresentalions were made Io u5 by the management and Counci]. Please read these representations Ca￿fullY and if you agree with our tmderstandin& please sxgn and retum a copy OE tbis letter to us as LxTrnfirniation of this. Representatlon You acknowledsed as tNstees your respmsibility for making acakrate repre5enlation5 to us and for the accounts which we have prepared for the d￿rity. Y(yu confirnied that all accountin8 records had been made available to Us for the Pu[w￿ of the independent examination and that a]1 the transaclions undertaken by the charity had been properly reflecied and retorded in the accounttng reeords. All other records and related Informatio￿ imcludimg minutes of all managemenl and trustees, meebw. had been made available tolls. You confirmed that the d)arity had no liabilities or conttnsent liabiknties other than tI￿se disclosed in the ￿e0￿￿t8. You confirmed that there have been no events Sin￿ the balan￿ sheet date which wuired disdosing or which would materially affert the amounts in the accounts. other than tlu)se already disclosed or induded in the accounts. You confRrmed that the clwity has not had, at any ti￿e during the perio(L any arrangement, tTan5action or agreement to Pro￿de credit faalitie5 (includin8 advances artd crcdits granted by the charity} for trustees, not to provide guaiantees of any kind on behalf of the trustees. ICA£W CHA￿ERED ACCOUPITNJqTS IN PEOPLE 49 BHIVA | .4nnual Refviirt eAccount.Y 2()25

BHIVA British HIV Association Hackeryoung Chartered Accountant5 Continued Briti$h Htv Asso(iation You conf1rn￿a that you have disdosed to us all related paty transactionb relevant to the charity attd that you are not aware of any further related party matters that requxre di8dosure. You confirmed that the dwity has not contracted for any capital expenditure other than as disclosed in the accounts. You confirnied you arenot aware of any pogsible or actual Instan￿ of non-eompliantr with laws and re8ulations which provide a legal framework within which the charity conducts its business and which are LEntral to the charl￿S ability to conduct its busxness. You confinned thaL having considered your ext*dations and intentions for the next twelve month5 and the availability of woIking capitaL the charity is 8 soing concer io You confinned the following speafic representations made to us during the course of preparing your accounts and our independent examination.. a. You confiTmed there were no employees durins the year b. You confirnied that ail liabilities relating to the year ended 31 DeceYnbeT 2023 had been Eully recosnised. YOUTS faAthfully W,,U¢rY cyilc We confirm that we have read and under5tocxl the contents of this letter and agree that it accurately fleets the r sentations made to you by the trustees durins the course of preparing the On behalf of the board 0£ tN5tee5 IGAEW IN PEOPLE Gold ACCOWIANIS BHIVA l AnnualRePDrt &.4ccount.5' 21?25 50

51

==> picture [225 x 310] intentionally omitted <==

==> picture [74 x 43] intentionally omitted <==

www.bhiva.org

BHIVA | Annual Report & Accounts 2023

© British HIV Association (BHIVA) October 2024